Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120 on ClinicalTrials.gov · last registry update 2021-02-25

A small phase 4 — 37 participants, against a typical 75. The sponsor logged completion for November 2013. Primary outcome, as filed: Change from baseline in HbA1c at six months.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mountain Diabetes and Endocrine Center
Sponsor type: Other
Enrollment: 37
Started: 2011-12
Primary completion: 2013-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from baseline in HbA1c at six months

Conditions studied

Diabetes Mellitus, Type II

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.